Search

MSK experts presented findings from their latest foundational and translational oncology research at the 2026 AACR Annual Meeting. Highlights included treatment of early-stage rectal cancer with protein inhibitors targeting HER2, recent data from the personalized RNA vaccine trial for pancreatic cancer, and development of a framework to understand biomarkers and vulnerabilities during the early to late stages of transitions from lung cancer-enabling adenomas to neuroendocrine lineage plasticity.

… Tuesday, April 21, 2026 Memorial Sloan Kettering Cancer Center (MSK) experts presented findings from their latest foundational and translational oncology research at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17 to 22 in San Diego. Highlights included treatment

Cytoreductive surgery for advanced ovarian cancer is safe in older women, even those who present with frailty.

… Thursday, September 19, 2019 Cytoreductive surgery for advanced ovarian cancer is safe in older women, even those who present with frailty, according to our recent prospective study of 42 patients treated at Memorial Sloan Kettering Cancer Center. Despite a high rate of preoperative impairments, there

Memorial Sloan Kettering Cancer Center (MSK) is now recognized as the first dedicated cancer center in the United States to be designated as a qualified provider-led entity (QPLE) under Medicare’s program for appropriate use criteria (AUC). This designation allows MSK to establish best practice standards for the use of CT scans, MRI, and nuclear medicine imaging from initial screening and diagnosis through all stages of cancer care, including survivorship.

… Tuesday, September 19, 2017 New York, NY - Memorial Sloan Kettering Cancer Center (MSK) has become the first dedicated cancer center in the U.S. to be designated a qualified provider-led entity (QPLE) under the Medicare Appropriate Use Criteria (AUC) program. This designation allows MSK to establish

Joan Massagué, Chair of the Cancer Biology and Genetics Program in the Sloan Kettering Institute, has been named the recipient of two prestigious awards.

… Friday, May 1, 2009 Summary Joan Massagué, Chair of the Cancer Biology and Genetics Program in the Sloan Kettering Institute, has been named the recipient of two prestigious awards. Joan Massagué , Chair of the Cancer Biology and Genetics Program in the Sloan Kettering Institute , has been named the

Research led by Josie Robertson Investigator Karuna Ganesh provided clues that microbiomes might explain the increase in colorectal cancer among younger patients.

… Wednesday, April 19, 2023 At a worldwide gathering of the American Association for Cancer Research (AACR), Memorial Sloan Kettering Cancer Center (MSK) scientists presented new insights into the connection between cancer and the gut microbiome, often referred to as the “forgotten organ.” Their findings

A leader in developing better treatments for a range of blood cancers, Dr. Omar Abdel-Wahab is only the second person from MSK to receive the Paul Marks Prize for Cancer Research. 

… Monday, December 1, 2025 For more than two decades, physician-scientist Omar Abdel-Wahab, MD , has been known around Memorial Sloan Kettering Cancer Center (MSK) for his insight, knowledge, and creativity as a cancer researcher.   Now he will also be known as a Paul Marks Prize winner , the first recipient

Andy Minn, MD, PhD, will return to Memorial Sloan Kettering Cancer Center (MSK) as the inaugural Chair of MSK’s new Immuno-Oncology Program in August.

… Thursday, May 15, 2025 Andy Minn, MD, PhD, will return to Memorial Sloan Kettering Cancer Center (MSK) as the inaugural Chair of MSK’s new Immuno-Oncology Program in August. This is a full-circle moment for Dr. Minn, a renowned physician-scientist, who completed his postdoctoral training with  Joan Massagué

Memorial Sloan Kettering Cancer Center has announced that Oren Cahlon, MD, a renowned radiation oncologist and expert in proton therapy, will assume the position of Associate Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network. With this appointment, which is effective immediately, Dr. Cahlon will help oversee the network’s outpatient clinical programs, which span seven locations across New York and New Jersey.

… Friday, November 23, 2018 Memorial Sloan Kettering Cancer Center has announced that Oren Cahlon, MD , a renowned radiation oncologist and expert in proton therapy, will assume the position of Associate Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network. With this appointment

Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman, Langerhans Histiocytosis), who do not harbor the BRAF V600 mutation. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma. This designation was granted based on data submitted by MSK, in collaboration with Genentech, a member of the Roche Group, from a phase II trial of single-agent cobimetinib for adults with histiocytic disorders (published in Nature in March 2019 by Eli Diamond, MD; Omar Abdel-Wahab, MD; and David Hyman, MD).

… Wednesday, October 2, 2019 Bottom Line: Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman

A Black community leader seeks prompt treatment for prostate cancer, avoiding the harsh toll the disease often takes on men like him.

… Thursday, November 2, 2023 Prostate cancer takes a severe toll on Black men.   Prompt diagnosis and treatment is especially important for good outcomes. Larry Scott Blackmon was stunned when actor Chadwick Boseman passed away from colon cancer in August 2020. Several months later, Larry’s annual checkup